SOFIE
7
3
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
29%
2 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
Role: collaborator
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Role: lead
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
Role: lead
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
Role: collaborator
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
Role: lead
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Role: lead
Novel Diagnostic and Prognostic Predictors in Fabry Cardiomyopathy: Proof of Concept in a Rare Disease
Role: collaborator
All 7 trials loaded